echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Blockbuster: The first clinical results of the first domestic CD3 recruiting bi-antibody phase I are released

    Blockbuster: The first clinical results of the first domestic CD3 recruiting bi-antibody phase I are released

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 13, the official website of the 2021 European Society of Medical Oncology (ESMO) annual meeting officially announced the progress of many clinical studies in the form of electronic posters
    .


    Among them, the report of the bispecific antibody EpCAM/CD3 bi-antibody from Wuhan Youzhiyou Biopharmaceutical is particularly eye-catching


    Among them, the report of the bispecific antibody EpCAM/CD3 bi-antibody from Wuhan Youzhiyou Biopharmaceutical is particularly eye-catching


    The results of the EpCAM/CD3 double antibody released by Wuhan Youzhiyou are very good, which brings a positive signal to the development of CD3 recruiting double antibody in the field of non-hematological tumors
    .


    According to the China Drug Clinical Trial Registration and Information Disclosure Platform, Wuhan Youzhiyou EpCAM/CD3 has been led by Director Xu Jianming of Beijing 301 Hospital to carry out Phase II clinical trials.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.